References
- Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711–720. .
- Santos RD, Gidding S, Hegele RA, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management; a consensus statement from the international atherosclerosis society severe familial hypercholesterolemia panel. Lancet Diabetes Endocrinol. 2016;4:850–861.
- Blom DJ, Raal FJ, Santos RD, et al. Lomitapide and mipomersen-inhibiting microsomal triglyceride transfer protein (MTP) and apoB100 synthesis. Curr Atheroscler Rep. 2019;21:48. .
- Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacological inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377:211–221.
- Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377:296–298. .
- Regeneron. FDA accepts evinacumab biologics license application for priority review as a treatment for patients with HoFH, an ultra-rare inherited form of high cholesterol. [cited 2020 Oct 19]. Available from: https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-evinacumab-biologics-license-application-priority
- Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381:1557–1567.
- Anagnostis P, Vaitsi K, Mintziori G, et al. Non-coronary atherosclerotic cardiovascular disease in patient with familial hypercholesterolaemia. Curr Med Res Opin. 2020;36:731–740.
- Ahmad Z, Banerjee P, Hamon S, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140:470–486. .
- Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Expert Opin Drug Saf. 2019;18:611–621.
- ClinicalTrials.gov Evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia. cited 2020 Oct 12. Available from: https://clinicaltrials.gov/ct2/show/NCT03409744?term=evinacumab&draw=2&rank=3
- Bajaj A, Cuchel M. Homozygous familial hypercholesterolemia: what treatments are on the horizon? Curr Opin Lipidol. 2020;31:119–124.
- ClinicalTrials.gov A gene therapy study for homozygous familial hypercholesterolemia (HoFH). [cited 2020 Oct 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02651675?term=nct+02651675&draw=2&rank=1
- ClinicalTrials.gov Study of evinacumab (REGN 1500) in participants with persistent hypercholesterolemia. [cited 2020 Oct 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03175367?term=evinacumab&draw=2&rank=6
- ClinicalTrials.gov Safety and efficacy following repeat-dose of evinacumab (anti-ANGPTL3) in patients with severe hypertriglyceridemia (Shtg) at risk of acute pancreatitis. [cited 2020 Oct 12]. Availabe from: https://clinicaltrials.gov/ct2/show/NCT03452228?term=evinacumab&draw=2&rank=2